Stimuli-sensitive Systems-an emerging delivery system for drugs
Source abstract
Abstract
OBJECTIVES: Development of controlled and sustained drug delivery system (DDS) remains a great thrust of human beings for the successful delivery of drugs due to various drawbacks of existing systems. In order to overcome these drawbacks, various stimuli-sensitive DDSs were developed in the recent years. KEY FINDINGS: Stimuli are a state of responsiveness to sensory stimulation or excitability. Stimuli sensitive systems are those systems which deal with the changes in the physiology of body with respective to the environment changes. These systems may be very beneficial for the controlled and sustained delivery of drug in the body if proper work would be carried out on these types of systems. Controlled drug delivery became the standard criteria in modern pharmaceutical product design and an intensive research is still going on in achieving much better drug product with features like effectiveness, reliability, and safety. Many changes like photo and light, temperature, pH, ion, glucose, and redox affect the release of drug from the delivery system. These stimuli-sensitive systems are used for various purposes in various forms like in parenteral, ocular, peroral, rectal, vaginal, nasal, dermal and transdermal drug delivery. SUMMARY: Various literature surveys revealed that stimuli-sensitive DDSs can be explored as a potential tool for the delivery of a variety of macromolecules that are not effectively delivered by conventional techniques.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Advanced Drug Delivery Systems · Cancer Research and Treatment
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (64)
Show source-provided references
1. Abraham S · Pak J Pharm Sci · 2009 · 22 · 175
2. 10.1517/17425247.3.5.57310.1517/17425247.3.5.573 ↗
3. 10.1104/pp.122.2.50510.1104/pp.122.2.505 ↗
4. 10.1016/j.addr.2009.07.00210.1016/j.addr.2009.07.002 ↗
5. 10.1023/A:100579871519210.1023/A:1005798715192 ↗
6. 10.1016/j.ijpharm.2007.03.00410.1016/j.ijpharm.2007.03.004 ↗
7. 10.1002/adma.20060195810.1002/adma.200601958 ↗
8. Balasubramaniam J · Acta Pharm · 2003 · 53 · 251
9. 10.1517/17425247.5.10.107710.1517/17425247.5.10.1077 ↗
10. 10.1016/j.carbpol.2009.12.04710.1016/j.carbpol.2009.12.047 ↗
11. 10.1016/j.ijpharm.2011.05.06010.1016/j.ijpharm.2011.05.060 ↗
12. 10.1007/s11095-006-0284-810.1007/s11095-006-0284-8 ↗
13. Deshmukh PK · Int J Pharm Bio Sci · 2010 · 6 · 211
14. 10.1016/j.ijpharm.2003.07.01410.1016/j.ijpharm.2003.07.014 ↗
15. Dzulkefli NA · ICSE. · 2008 · 227
16. Fadel M · J Control Release · 2007 · 143 · 78
17. 10.1016/j.jconrel.2007.12.01710.1016/j.jconrel.2007.12.017 ↗
18. 10.1016/S1359-6446(02)02255-910.1016/S1359-6446(02)02255-9 ↗
19. 10.1016/S0168-3659(99)00075-910.1016/S0168-3659(99)00075-9 ↗
20. 10.1016/j.polymer.2005.07.03410.1016/j.polymer.2005.07.034 ↗
21. 10.1007/s10971-007-1661-410.1007/s10971-007-1661-4 ↗
22. Kavitha K · Int J PharmTech Res · 2011 · 3 · 702
23. 10.1016/0168-3659(90)90132-D10.1016/0168-3659(90)90132-D ↗
24. 10.1517/1742524090353065110.1517/17425240903530651 ↗
25. 10.1016/j.biomaterials.2010.05.04510.1016/j.biomaterials.2010.05.045 ↗
26. 10.1016/j.jconrel.2007.06.01210.1016/j.jconrel.2007.06.012 ↗
27. 10.1016/j.jcis.2008.08.03910.1016/j.jcis.2008.08.039 ↗
28. 10.1002/jbm.b.3034210.1002/jbm.b.30342 ↗
29. 10.1016/j.addr.2007.11.00910.1016/j.addr.2007.11.009 ↗
30. 10.1016/j.actbio.2010.02.01410.1016/j.actbio.2010.02.014 ↗
31. Liu Y · Am J Pharm Sci · 2010 · 11 · 610
32. 10.1016/j.ijpharm.2006.01.02910.1016/j.ijpharm.2006.01.029 ↗
33. 10.1016/S0168-3659(96)01525-810.1016/S0168-3659(96)01525-8 ↗
34. 10.1016/j.biomaterials.2008.10.00810.1016/j.biomaterials.2008.10.008 ↗
35. 10.1080/0363904070158062210.1080/03639040701580622 ↗
36. 10.1016/j.jconrel.2003.10.02710.1016/j.jconrel.2003.10.027 ↗
37. 10.1038/nature0136210.1038/nature01362 ↗
38. 10.1016/j.jconrel.2009.08.02210.1016/j.jconrel.2009.08.022 ↗
39. 10.1517/17425247.3.5.56310.1517/17425247.3.5.563 ↗
40. Mishra DN · Daru · 2008 · 16 · 1
41. 10.1016/S0169-409X(01)00241-110.1016/S0169-409X(01)00241-1 ↗
42. 10.1016/j.jconrel.2006.07.00710.1016/j.jconrel.2006.07.007 ↗
43. 10.1016/j.biomaterials.2009.05.07310.1016/j.biomaterials.2009.05.073 ↗
44. 10.1002/jbm.82025021010.1002/jbm.820250210 ↗
45. 10.1023/A:101609010397910.1023/A:1016090103979 ↗
46. 10.1006/jcis.1998.569210.1006/jcis.1998.5692 ↗
47. 10.1016/j.addr.2006.09.02010.1016/j.addr.2006.09.020 ↗
48. 10.1016/0378-5173(89)90101-410.1016/0378-5173(89)90101-4 ↗
49. 10.1016/j.addr.2006.09.01810.1016/j.addr.2006.09.018 ↗
50. 10.1007/s11095-005-8343-010.1007/s11095-005-8343-0 ↗
51. 10.1016/j.jconrel.2006.12.01910.1016/j.jconrel.2006.12.019 ↗
52. 10.1039/b807353h10.1039/b807353h ↗
53. 10.1007/s10895-013-1163-410.1007/s10895-013-1163-4 ↗
54. 10.1080/1071754050030916410.1080/10717540500309164 ↗
55. Sun G · Annu Rev · 2011 · 20975
56. 10.1360/032011-77110.1360/032011-771 ↗
57. 10.1016/S0142-9612(00)00050-810.1016/S0142-9612(00)00050-8 ↗
58. 10.1016/S0169-409X(01)00189-210.1016/S0169-409X(01)00189-2 ↗
59. Vodithala S · Int J Curr Pharm Res · 2010 · 2 · 33
60. Vodovozova E.L. · Biochem Mol Biol Int · 1998 · 44 · 543
61. Vyas SP, Khar RK. 2002. Targeted and controlled drug delivery of novel carrier system. CBS Publishers and Distributors Ltd, 369–370.
62. 10.1517/14712598.7.5.58710.1517/14712598.7.5.587 ↗
63. 10.1016/0168-3659(94)90161-910.1016/0168-3659(94)90161-9 ↗
64. 10.1016/j.carbpol.2010.11.00910.1016/j.carbpol.2010.11.009 ↗